Tamron Q2 FY2026: Revenue up 3.8%, operating profit dips; raises FY sales target
Revenue
¥43.3B
+3.8%
Full-year forecast
¥93.0B
Operating Profit
¥7.7B
-16.5%
Full-year forecast
¥18.5B
Net Income
¥6.2B
-9.9%
Full-year forecast
¥13.7B
Operating Margin
17.8%
Tamron's Q2 FY2026 revenue rose 3.8% to ¥43.28 billion, but operating profit dropped 16.5% to ¥7.69 billion on weak OEM camera lens sales. Stronger industrial optics drove it to raise full-year revenue guidance to ¥93 billion, and it plans a dividend hike to ¥51 from ¥36.25.
Earnings Summary
The first half was marked by a 3.8% revenue increase to ¥43.28 billion, supported by strong industrial demand despite an 8.2% drop in photography-related sales. Operating profit fell 16.5% to ¥7.69 billion, reflecting weak OEM orders and a 7.5% rise in SG&A, including R&D, to ¥10.44 billion. Net income attributable to owners of the parent declined 9.9% to ¥6.20 billion. Management expects the photography OEM slump to persist, but sees cost reductions and a weaker yen (full-year assumptions: USD/JPY 160, EUR/JPY 180) cushioning the impact. It targets record full-year revenue of ¥93 billion and operating profit of ¥18.5 billion, up 11.2%.
Segment Performance
| Segment | Revenue (¥mn) | YoY | Operating Profit (¥mn) | YoY | Margin |
|---|---|---|---|---|---|
| Photography-related | 27,534 | -8.2% | 5,943 | -29.3% | 21.6% |
| Surveillance & FA | 7,711 | +29.0% | 1,026 | +10.5% | 13.3% |
| Mobility & Healthcare and Other | 8,035 | +39.6% | 1,987 | +48.0% | 24.7% |
Photography-related business saw own-brand lens sales perform well in Europe, the US and India on new products for Sony E-mount and Nikon Z-mount, but excess inventory in China and a prolonged OEM order slump hit results. Revenue fell to ¥27.53 billion (-8.2%) and operating profit to ¥5.94 billion (-29.3%). OEM weakness is expected to take time to recover.
Surveillance & FA business posted double-digit growth in surveillance camera lenses and modules for developed markets, driven by demand for higher precision and resolution. Factory automation and machine vision lenses also returned to double-digit growth as customer inventory adjustments ended. Revenue rose to ¥7.71 billion (+29.0%), operating profit to ¥1.03 billion (+10.5%), with a margin of 13.3%.
Mobility & Healthcare and Other business benefited from automotive camera lenses capturing ADAS demand, with a recovery in China. Medical lenses, notably ultra-small rigid endoscope lenses and fluorescence-guided surgery filters, saw revenue more than double year-on-year. Revenue surged to ¥8.04 billion (+39.6%) and operating profit to ¥1.99 billion (+48.0%), achieving a 24.7% margin, surpassing photography. Combined operating profit of the three industrial segments approached half of photography's, marking a turning point in earnings structure.
| Segment | Revenue | Share | Op. Profit | Op. Margin |
|---|---|---|---|---|
| Photography-related business | ¥27.5B | 64% | ¥5.9B | 21.6% |
| Surveillance & FA related business | ¥7.7B | 18% | ¥1.0B | 13.3% |
| Mobility & Healthcare and Other businesses | ¥8.0B | 19% | ¥2.0B | 24.7% |
Financial Position and Capital Policy
Total assets at the half-year stood at ¥109.24 billion, up ¥3.19 billion from end-FY2025, mainly on higher receivables and raw materials. Liabilities fell ¥291 million to ¥19.84 billion, while net assets rose ¥3.49 billion to ¥89.40 billion, lifting the equity ratio to 81.8%.
Operating cash flow was ¥5.89 billion (vs. ¥7.64 billion a year earlier), investing cash outflow for capex totaled ¥3.20 billion, and financing cash outflow from dividend payments contracted to ¥4.14 billion (from ¥8.99 billion). Cash and equivalents closed at ¥34.63 billion.
On dividends, the company plans an annual payout of ¥51 per share (interim ¥20, year-end ¥31) for FY2026, a sharp increase from the adjusted ¥36.25 in FY2025. Shareholder returns will focus on dividends, with minimal share buybacks.
Full-Year Outlook
First-half results were on track, with Mobility & Healthcare exceeding plan, prompting a revision only in revenue. The company now targets sales of ¥93 billion (up 9.3% from the previous year), while keeping operating profit at ¥18.5 billion, ordinary profit at ¥18.5 billion and net profit at ¥13.69 billion unchanged.
| Item | Previous Forecast | Revised Forecast | FY2025 Actual | Change |
|---|---|---|---|---|
| Revenue (¥mn) | 91,000 | 93,000 | - | +9.3% |
| Operating profit (¥mn) | 18,500 | 18,500 | - | +11.2% |
| Ordinary profit (¥mn) | 18,500 | 18,500 | - | +10.8% |
| Net profit (¥mn) | 13,690 | 13,690 | - | +16.4% |
Second-half assumptions incorporate a significantly weaker yen: USD/JPY 160 (previously 148) and EUR/JPY 180 (previously 175). The company expects double-digit revenue and profit growth in H2, with all segments expanding. The full-year operating profit target of ¥18.5 billion (up 11%) is a record, underpinned by industrial growth, without relying on an OEM recovery in photography.
Risks and Challenges
Management highlighted the following risks:
- Rising energy costs and logistics disruptions from Middle East tensions could inflate procurement and freight expenses, pressuring margins.
- Prolonged weakness in OEM demand for photography products may undermine full-year profit targets in a historically high-margin segment.
- Excess inventory in China and a protracted real estate downturn pose demand risks.
- Sharp forex swings: current assumptions are heavily skewed toward a weak yen, so an unexpected yen appreciation could quickly erode earnings.
- Potential US or European trade policy changes, including tariff hikes, could disrupt the supply chain.
Analyst take
Tamron’s strength lies in leveraging its optical expertise from camera lenses into high-growth areas like automotive and medical, diversifying earnings. This half-year proved the strategy, as industrial arms compensated for the photography decline. Notably, Mobility & Healthcare posted a 24.7% margin, rivaling the photo unit. However, heavy reliance on a weak yen assumption for the full-year plan warrants caution; if the yen strengthens, the outlook could reverse. Aggressive R&D spending weighs near-term but builds future competitiveness. Over the long term, structural growth in automotive and medical lenses and diminishing dependence on photography could drive a valuation re-rating, while the commitment to rising dividends adds appeal.